Clinical pharmacology of novel anti-Alzheimer disease modifying medications

Current Topics in Medicinal Chemistry

Volumn 13, Issue 15, 2013, Pages 1853-1863

  Caraci, Filippo ^a,b   Bosco, Paolo ^b   Leggio, Gian Marco ^a   Malaguarnera, Michele ^a   Drago, Filippo ^a   Bucolo, Claudio ^a   Salomone, Salvatore ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b OASI RESEARCH INSTITUTE IRCCS   (Italy)

Author keywords

Alzheimer's disease; Clinical trials; Disease modifying drug; amyloid

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMLODIPINE; AMYLOID BETA PROTEIN; AN 7192; AVAGACESTAT; BAPINEUZUMAB; BEGACESTAT; BRYOSTATIN 1; CRENEZUMAB; CURCUMIN; ELND 005; EPIGALLOCATECHIN GALLATE; ETAZOLATE; GAMMA SECRETASE; GANTENERUMAB; GRAPE SEED EXTRACT; HOMOTAURINE; NILVADIPINE; PIOGLITAZONE; PONEZUMAB; PSYCHOTROPIC AGENT; ROSIGLITAZONE; SCYLLOCYCLOHEXANEHEXOL; SEMAGACESTAT; SOLANEZUMAB; TARENFLURBIL; TAU PROTEIN; UNCLASSIFIED DRUG; VANUTIDE CRIDIFICAR;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; IMMUNOTHERAPY; MENINGOENCEPHALITIS; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROPSYCHOLOGICAL TEST; NONHUMAN; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; UNSPECIFIED SIDE EFFECT;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG DESIGN; EARLY DIAGNOSIS; FLOCCULATION; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; NOOTROPIC AGENTS; TAU PROTEINS;

EID: 84887942754     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/15680266113139990141     Document Type: Review

References (115)

1. Brookmeyer, R.; Johnson, E.; Ziegler-Graham, K.; Arrighi, H. M., Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 2007, 3 (3), 186-91.
2. Ballard, C. G.; Chalmers, K. A.; Todd, C.; McKeith, I. G.; O'Brien, J. T.; Wilcock, G.; Love, S.; Perry, E. K., Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies. Neurology. 2007, 68 (20), 1726-9.
3. Chalmers, K. A.; Wilcock, G. K.; Vinters, H. V.; Perry, E. K.; Perry, R.; Ballard, C. G.; Love, S., Cholinesterase inhibitors may increase phosphorylated tau in Alzheimer's disease. J Neurol. 2009, 256 (5), 717-20.
4. McKhann, G. M.; Knopman, D. S.; Chertkow, H.; Hyman, B. T.; Jack, C. R., Jr.; Kawas, C. H.; Klunk, W. E.; Koroshetz, W. J.; Manly, J. J.; Mayeux, R.; Mohs, R. C.; Morris, J. C.; Rossor, M. N.; Scheltens, P.; Carrillo, M. C.; Thies, B.; Weintraub, S.; Phelps, C. H., The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7 (3), 263-9.
5. Albert, M. S.; DeKosky, S. T.; Dickson, D.; Dubois, B.; Feldman, H. H.; Fox, N. C.; Gamst, A.; Holtzman, D. M.; Jagust, W. J.; Petersen, R. C.; Snyder, P. J.; Carrillo, M. C.; Thies, B.; Phelps, C. H., The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7 (3), 270-9.
6. Sperling, R. A.; Aisen, P. S.; Beckett, L. A.; Bennett, D. A.; Craft, S.; Fagan, A. M.; Iwatsubo, T.; Jack, C. R., Jr.; Kaye, J.; Montine, T. J.; Park, D. C.; Reiman, E. M.; Rowe, C. C.; Siemers, E.; Stern, Y.; Yaffe, K.; Carrillo, M. C.; Thies, B.; Morrison-Bogorad, M.; Wagster, M. V.; Phelps, C. H., Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7 (3), 280-92.
7. Hampel, H.; Lista, S.; Khachaturian, Z. S., Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot. Alzheimers Dement. 2012, 8 (4), 312-36.
8. Caroli, A.; Frisoni, G. B., The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort. Neurobiol Aging. 2010, 31 (8), 1263-74.
9. Hardy, J., The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem. 2009, 110 (4), 1129-34.
10. Ewers, M.; Sperling, R. A.; Klunk, W. E.; Weiner, M. W.; Hampel, H., Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci. 2011, 34 (8), 430-42.
11. Fagan, A. M.; Mintun, M. A.; Mach, R. H.; Lee, S. Y.; Dence, C. S.; Shah, A. R.; LaRossa, G. N.; Spinner, M. L.; Klunk, W. E.; Mathis, C. A.; DeKosky, S. T.; Morris, J. C.; Holtzman, D. M., Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006, 59 (3), 512-9.
12. Ost, M.; Nylen, K.; Csajbok, L.; Ohrfelt, A. O.; Tullberg, M.; Wikkelso, C.; Nellgard, P.; Rosengren, L.; Blennow, K.; Nellgard, B., Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology. 2006, 67 (9), 1600-4.
13. Hampel, H.; Burger, K.; Pruessner, J. C.; Zinkowski, R.; DeBernardis, J.; Kerkman, D.; Leinsinger, G.; Evans, A. C.; Davies, P.; Moller, H. J.; Teipel, S. J., Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol. 2005, 62 (5), 770-3.
14. Hampel, H.; Shen, Y.; Walsh, D. M.; Aisen, P.; Shaw, L. M.; Zetterberg, H.; Trojanowski, J. Q.; Blennow, K., Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp Neurol. 2010, 223 (2), 334-46.
15. Blennow, K.; Hampel, H.; Weiner, M.; Zetterberg, H., Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010, 6 (3), 131-44.
16. Anello, G.; Gueant-Rodriguez, R. M.; Bosco, P.; Gueant, J. L.; Romano, A.; Namour, B.; Spada, R.; Caraci, F.; Pourie, G.; Daval, J. L.; Ferri, R., Homocysteine and methylenetetrahydrofolate reductase polymorphism in Alzheimer's disease. Neuroreport. 2004, 15 (5), 859-61.
17. Zhuo, J. M.; Wang, H.; Pratico, D., Is hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD marker, or neither? Trends Pharmacol Sci. 2011, 32 (9), 562-71.
18. Lichtenthaler, S. F.; Haass, C.; Steiner, H., Regulated intramembrane proteolysis--lessons from amyloid precursor protein processing. J Neurochem. 2011, 117 (5), 779-96.
19. Landreth, G.; Jiang, Q.; Mandrekar, S.; Heneka, M., PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics. 2008, 5 (3), 481-9.
20. Watson, G. S.; Cholerton, B. A.; Reger, M. A.; Baker, L. D.; Plymate, S. R.; Asthana, S.; Fishel, M. A.; Kulstad, J. J.; Green, P. S.; Cook, D. G.; Kahn, S. E.; Keeling, M. L.; Craft, S., Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry. 2005, 13 (11), 950-8.
21. Gold, M.; Alderton, C.; Zvartau-Hind, M.; Egginton, S.; Saunders, A. M.; Irizarry, M.; Craft, S.; Landreth, G.; Linnamagi, U.; Sawchak, S., Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord. 2010, 30 (2), 131-46.
22. Tomita, T., Secretase inhibitors and modulators for Alzheimer's disease treatment. Expert Rev Neurother. 2009, 9 (5), 661-79.
23. Shen, J.; Kelleher, R. J., 3rd, The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. Proc Natl Acad Sci U S A. 2007, 104 (2), 403-9.
24. Henley, D. B.; May, P. C.; Dean, R. A.; Siemers, E. R., Development of semagacestat (LY450139), a functional gammasecretase inhibitor, for the treatment of Alzheimer's disease. Expert Opin Pharmacother. 2009, 10 (10), 1657-64.
25. Bateman, R. J.; Siemers, E. R.; Mawuenyega, K. G.; Wen, G.; Browning, K. R.; Sigurdson, W. C.; Yarasheski, K. E.; Friedrich, S. W.; Demattos, R. B.; May, P. C.; Paul, S. M.; Holtzman, D. M., A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol. 2009, 66 (1), 48-54.
26. Schor, N. F., What the halted phase III gamma-secretase inhibitor trial may (or may not) be telling us. Ann Neurol. 2011, 69 (2), 237-9.
27. Yan, C.; Liang, Y.; Nylander, K. D.; Wong, J.; Rudavsky, R. M.; Saragovi, H. U.; Schor, N. F., p75-nerve growth factor as an antiapoptotic complex: independence versus cooperativity in protection from enediyne chemotherapeutic agents. Mol Pharmacol. 2002, 61 (4), 710-9.
28. Yan, C.; Mirnics, Z. K.; Portugal, C. F.; Liang, Y.; Nylander, K. D.; Rudzinski, M.; Zaccaro, C.; Saragovi, H. U.; Schor, N. F., Cholesterol biosynthesis and the pro-apoptotic effects of the p75 nerve growth factor receptor in PC12 pheochromocytoma cells. Brain Res Mol Brain Res. 2005, 139 (2), 225-34.
29. Rabizadeh, S.; Bitler, C. M.; Butcher, L. L.; Bredesen, D. E., Expression of the low-affinity nerve growth factor receptor enhances beta-amyloid peptide toxicity. Proc Natl Acad Sci U S A. 1994, 91 (22), 10703-6.
30. Martone, R. L.; Zhou, H.; Atchison, K.; Comery, T.; Xu, J. Z.; Huang, X.; Gong, X.; Jin, M.; Kreft, A.; Harrison, B.; Mayer, S. C.; Aschmies, S.; Gonzales, C.; Zaleska, M. M.; Riddell, D. R.; Wagner, E.; Lu, P.; Sun, S. C.; Sonnenberg-Reines, J.; Oganesian, A.; Adkins, K.; Leach, M. W.; Clarke, D. W.; Huryn, D.; Abou-Gharbia, M.; Magolda, R.; Bard, J.; Frick, G.; Raje, S.; Forlow, S. B.; Balliet, C.; Burczynski, M. E.; Reinhart, P. H.; Wan, H. I.; Pangalos, M. N.; Jacobsen, J. S., Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease. J Pharmacol Exp Ther. 2009, 331 (2), 598-608.
31. Tong, G.; Wang, J. S.; Sverdlov, O.; Huang, S. P.; Slemmon, R.; Croop, R.; Castaneda, L.; Gu, H.; Wong, O.; Li, H.; Berman, R. M.; Smith, C.; Albright, C. F.; Dockens, R. C., Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral gamma-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers. Clin Ther. 2012, 34 (3), 654-67.
32. Soares, H.; Raha, N.; Sikpi, M.; Liston, D.; Brodney, M.; Coffman, K.; Tate, B.; Qiu, R.; Wang, E. Q.; Li, X.; Hidi, R.; Banerjee, S.; Stanford, J.; Ereshefsky, L.; Fullerton, T., Aβ variability and effect of gamma secretase inhibition on cerebrospinal fluid levels of Aβ in healthy volunteers. Alzheimers Dement. 2009, 5 (4, Supplement), P252-P253.
33. Imbimbo, B. P.; Hutter-Paier, B.; Villetti, G.; Facchinetti, F.; Cenacchi, V.; Volta, R.; Lanzillotta, A.; Pizzi, M.; Windisch, M., CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. Br J Pharmacol. 2009, 156 (6), 982-93.
34. Green, R. C.; Schneider, L. S.; Amato, D. A.; Beelen, A. P.; Wilcock, G.; Swabb, E. A.; Zavitz, K. H., Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA. 2009, 302 (23), 2557-64.
35. Imbimbo, B. P.; Giardina, G. A., gamma-Secretase Inhibitors and Modulators for the Treatment of Alzheimer's Disease: Disappointments and Hopes. Curr Top Med Chem. 2011.
36. Giuffrida, M. L.; Caraci, F.; De Bona, P.; Pappalardo, G.; Nicoletti, F.; Rizzarelli, E.; Copani, A., The monomer state of beta-amyloid: where the Alzheimer's disease protein meets physiology. Rev Neurosci. 2010, 21 (2), 83-93.
37. Plant, L. D.; Boyle, J. P.; Smith, I. F.; Peers, C.; Pearson, H. A., The production of amyloid beta peptide is a critical requirement for the viability of central neurons. J Neurosci. 2003, 23 (13), 5531-5.
38. Giuffrida, M. L.; Caraci, F.; Pignataro, B.; Cataldo, S.; De Bona, P.; Bruno, V.; Molinaro, G.; Pappalardo, G.; Messina, A.; Palmigiano, A.; Garozzo, D.; Nicoletti, F.; Rizzarelli, E.; Copani, A., Beta-amyloid monomers are neuroprotective. J Neurosci. 2009, 29 (34), 10582-7.
39. Kamenetz, F.; Tomita, T.; Hsieh, H.; Seabrook, G.; Borchelt, D.; Iwatsubo, T.; Sisodia, S.; Malinow, R., APP processing and synaptic function. Neuron. 2003, 37 (6), 925-37.
40. Wang, H.; Song, L.; Laird, F.; Wong, P. C.; Lee, H. K., BACE1 knock-outs display deficits in activity-dependent potentiation of synaptic transmission at mossy fiber to CA3 synapses in the hippocampus. J Neurosci. 2008, 28 (35), 8677-81.
41. Puzzo, D.; Privitera, L.; Leznik, E.; Fa, M.; Staniszewski, A.; Palmeri, A.; Arancio, O., Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J Neurosci. 2008, 28 (53), 14537-45.
42. Tate, B.; McKee, T. D.; Loureiro, R. M.; Dumin, J. A.; Xia, W.; Pojasek, K.; Austin, W. F.; Fuller, N. O.; Hubbs, J. L.; Shen, R.; Jonker, J.; Ives, J.; Bronk, B. S., Modulation of gamma-secretase for the treatment of Alzheimer's disease. Int J Alzheimers Dis. 2012, 2012 210756.
43. Marcade, M.; Bourdin, J.; Loiseau, N.; Peillon, H.; Rayer, A.; Drouin, D.; Schweighoffer, F.; Desire, L., Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing. J Neurochem. 2008, 106 (1), 392-404.
44. Vellas, B.; Sol, O.; Snyder, P. J.; Ousset, P. J.; Haddad, R.; Maurin, M.; Lemarie, J. C.; Desire, L.; Pando, M. P., EHT0202 in Alzheimer's disease: a 3-month, randomized, placebo-controlled, double-blind study. Curr Alzheimer Res. 2011, 8 (2), 203-12.
45. Yi, P.; Schrott, L.; Castor, T. P.; Alexander, J. S., Bryostatin-1 vs. TPPB: dose-dependent APP processing and PKC-alpha,-delta, and-epsilon isoform activation in SH-SY5Y neuronal cells. J Mol Neurosci. 2012, 48 (1), 234-44.
46. Snow, A. D.; Cummings, J.; Lake, T.; Hu, Q.; Esposito, L.; Cam, J.; Hudson, M.; Smith, E.; S., R., Exebryl-1: A novel small molecule currently in human clinical trials as a disease-modifying drug for the treatment of Alzheimer's disease. Alzheimers Dement. 2009, 5 (4 Supplement), P418.
47. Forette, F.; Seux, M. L.; Staessen, J. A.; Thijs, L.; Babarskiene, M. R.; Babeanu, S.; Bossini, A.; Fagard, R.; Gil-Extremera, B.; Laks, T.; Kobalava, Z.; Sarti, C.; Tuomilehto, J.; Vanhanen, H.; Webster, J.; Yodfat, Y.; Birkenhager, W. H., The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med. 2002, 162 (18), 2046-52.
48. Hanon, O.; Forette, F., Prevention of dementia: lessons from SYST-EUR and PROGRESS. J Neurol Sci. 2004, 226 (1-2), 71-4.
49. Paris, D.; Bachmeier, C.; Patel, N.; Quadros, A.; Volmar, C. H.; Laporte, V.; Ganey, J.; Beaulieu-Abdelahad, D.; Ait-Ghezala, G.; Crawford, F.; Mullan, M. J., Selective antihypertensive dihydropyridines lower Abeta accumulation by targeting both the production and the clearance of Abeta across the blood-brain barrier. Mol Med. 2011, 17 (3-4), 149-62.
50. Hanyu, H.; Hirao, K.; Shimizu, S.; Sato, T.; Kiuchi, A.; Iwamoto, T., Nilvadipine prevents cognitive decline of patients with mild cognitive impairment. Int J Geriatr Psychiatry. 2007, 22 (12), 1264-6.
51. Kennelly, S. P.; Abdullah, L.; Paris, D.; Parish, J.; Mathura, V.; Mullan, M.; Crawford, F.; Lawlor, B. A.; Kenny, R. A., Demonstration of safety in Alzheimer's patients for intervention with an anti-hypertensive drug Nilvadipine: results from a 6-week open label study. Int J Geriatr Psychiatry. 2011, 26 (10), 1038-45.
52. Kennelly, S. P.; Abdullah, L.; Paris, D.; Parish, J.; Mathura, V.; Mullan, M.; Crawford, F.; Lawlor, B. A.; Kenny, R. A., Demonstration of safety in Alzheimer's patients for intervention with an anti-hypertensive drug Nilvadipine: results from a 6-week open label study. Int J Geriatr Psychiatry. 2010.
53. NILVAD A European multicentre double-blind placebo-controlled phase III trial of nilvadIpine in mild to moderate Alzheimer's disease. http://ec. europa. eu/research/health/medicalresearch/human-development-and-ageing/projects/nilvad_en. html.
54. Shankar, G. M.; Bloodgood, B. L.; Townsend, M.; Walsh, D. M.; Selkoe, D. J.; Sabatini, B. L., Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007, 27 (11), 2866-75.
55. Walsh, D. M.; Selkoe, D. J., A beta oligomers-a decade of discovery. J Neurochem. 2007, 101 (5), 1172-84.
56. Gervais, F.; Paquette, J.; Morissette, C.; Krzywkowski, P.; Yu, M.; Azzi, M.; Lacombe, D.; Kong, X.; Aman, A.; Laurin, J.; Szarek, W. A.; Tremblay, P., Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging. 2007, 28 (4), 537-47.
57. Aisen, P. S.; Saumier, D.; Briand, R.; Laurin, J.; Gervais, F.; Tremblay, P.; Garceau, D., A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology. 2006, 67 (10), 1757-63.
58. Gauthier, S.; Aisen, P. S.; Ferris, S. H.; Saumier, D.; Duong, A.; Haine, D.; Garceau, D.; Suhy, J.; Oh, J.; Lau, W.; Sampalis, J., Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study. J Nutr Health Aging. 2009, 13 (6), 550-7.
59. Saumier, D.; Duong, A.; Haine, D.; Garceau, D.; Sampalis, J., Domain-specific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer's disease: ADAS-cog subscale results from the Alphase Study. J Nutr Health Aging. 2009, 13 (9), 808-12.
60. Faux, N. G.; Ritchie, C. W.; Gunn, A.; Rembach, A.; Tsatsanis, A.; Bedo, J.; Harrison, J.; Lannfelt, L.; Blennow, K.; Zetterberg, H.; Ingelsson, M.; Masters, C. L.; Tanzi, R. E.; Cummings, J. L.; Herd, C. M.; Bush, A. I., PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis. 2010, 20 (2), 509-16.
61. Adlard, P. A.; Cherny, R. A.; Finkelstein, D. I.; Gautier, E.; Robb, E.; Cortes, M.; Volitakis, I.; Liu, X.; Smith, J. P.; Perez, K.; Laughton, K.; Li, Q. X.; Charman, S. A.; Nicolazzo, J. A.; Wilkins, S.; Deleva, K.; Lynch, T.; Kok, G.; Ritchie, C. W.; Tanzi, R. E.; Cappai, R.; Masters, C. L.; Barnham, K. J.; Bush, A. I., Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron. 2008, 59 (1), 43-55.
62. Fenili, D.; Brown, M.; Rappaport, R.; McLaurin, J., Properties of scyllo-inositol as a therapeutic treatment of AD-like pathology. J Mol Med (Berl). 2007, 85 (6), 603-11.
63. Amijee, H.; Scopes, D. I., The quest for small molecules as amyloid inhibiting therapies for Alzheimer's disease. J Alzheimers Dis. 2009, 17 (1), 33-47.
64. Salloway, S.; Sperling, R.; Keren, R.; Porsteinsson, A. P.; van Dyck, C. H.; Tariot, P. N.; Gilman, S.; Arnold, D.; Abushakra, S.; Hernandez, C.; Crans, G.; Liang, E.; Quinn, G.; Bairu, M.; Pastrak, A.; Cedarbaum, J. M., A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology. 2011, 77 (13), 1253-1262.
65. Fox, N. C.; Black, R. S.; Gilman, S.; Rossor, M. N.; Griffith, S. G.; Jenkins, L.; Koller, M., Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology. 2005, 64 (9), 1563-72.
66. Mandel, S. A.; Amit, T.; Kalfon, L.; Reznichenko, L.; Weinreb, O.; Youdim, M. B., Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: special reference to epigallocatechin gallate (EGCG). J Alzheimers Dis. 2008, 15 (2), 211-22.
67. Town, T., Alternative Abeta immunotherapy approaches for Alzheimer's disease. CNS Neurol Disord Drug Targets. 2009, 8 (2), 114-27.
68. Lemere, C. A., Developing novel immunogens for a safe and effective Alzheimer's disease vaccine. Prog Brain Res. 2009, 175 83-93.
69. Bard, F.; Fox, M.; Friedrich, S.; Seubert, P.; Schenk, D.; Kinney, G. G.; Yednock, T., Sustained levels of antibodies against Abeta in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice. Exp Neurol. 2012, 238 (1), 38-43.
70. DeMattos, R. B.; Bales, K. R.; Cummins, D. J.; Paul, S. M.; Holtzman, D. M., Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science. 2002, 295 (5563), 2264-7.
71. Solomon, B.; Koppel, R.; Frankel, D.; Hanan-Aharon, E., Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci U S A. 1997, 94 (8), 4109-12.
72. Nicoll, J. A.; Barton, E.; Boche, D.; Neal, J. W.; Ferrer, I.; Thompson, P.; Vlachouli, C.; Wilkinson, D.; Bayer, A.; Games, D.; Seubert, P.; Schenk, D.; Holmes, C., Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol. 2006, 65 (11), 1040-8.
73. Morgan, D., Mechanisms of A beta plaque clearance following passive A beta immunization. Neurodegener Dis. 2005, 2 (5), 261-6.
74. Schenk, D.; Barbour, R.; Dunn, W.; Gordon, G.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; Khan, K.; Kholodenko, D.; Lee, M.; Liao, Z.; Lieberburg, I.; Motter, R.; Mutter, L.; Soriano, F.; Shopp, G.; Vasquez, N.; Vandevert, C.; Walker, S.; Wogulis, M.; Yednock, T.; Games, D.; Seubert, P., Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999, 400 (6740), 173-7.
75. Check, E., Nerve inflammation halts trial for Alzheimer's drug. Nature. 2002, 415 (6871), 462.
76. Wisniewski, T.; Frangione, B., Immunological and anti-chaperone therapeutic approaches for Alzheimer disease. Brain Pathol. 2005, 15 (1), 72-7.
77. Nicoll, J. A.; Wilkinson, D.; Holmes, C.; Steart, P.; Markham, H.; Weller, R. O., Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med. 2003, 9 (4), 448-52.
78. Holmes, C.; Boche, D.; Wilkinson, D.; Yadegarfar, G.; Hopkins, V.; Bayer, A.; Jones, R. W.; Bullock, R.; Love, S.; Neal, J. W.; Zotova, E.; Nicoll, J. A., Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008, 372 (9634), 216-23.
79. Kokjohn, T. A.; Roher, A. E., Antibody responses, amyloid-beta peptide remnants and clinical effects of AN-1792 immunization in patients with AD in an interrupted trial. CNS Neurol Disord Drug Targets. 2009, 8 (2), 88-97.
80. Lemere, C. A.; Masliah, E., Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol. 2010, 6 (2), 108-19.
81. Winblad, B.; Andreasen, N.; Minthon, L.; Floesser, A.; Imbert, G.; Dumortier, T.; Maguire, R. P.; Blennow, K.; Lundmark, J.; Staufenbiel, M.; Orgogozo, J. M.; Graf, A., Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol. 2012, 11 (7), 597-604.
82. Mandler, M.; Schmidt, W.; Mattner, F., Development of AFFITOPE Alzheimer vaccines: Results of phase I studies with AD01 and AD02. Alzheimers Dement. 2011, 7 (4), S793.
83. Bard, F.; Cannon, C.; Barbour, R.; Burke, R. L.; Games, D.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; Khan, K.; Kholodenko, D.; Lee, M.; Lieberburg, I.; Motter, R.; Nguyen, M.; Soriano, F.; Vasquez, N.; Weiss, K.; Welch, B.; Seubert, P.; Schenk, D.; Yednock, T., Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000, 6 (8), 916-9.
84. DeMattos, R. B.; Bales, K. R.; Cummins, D. J.; Dodart, J. C.; Paul, S. M.; Holtzman, D. M., Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2001, 98 (15), 8850-5.
85. Salloway, S.; Sperling, R.; Gilman, S.; Fox, N. C.; Blennow, K.; Raskind, M.; Sabbagh, M.; Honig, L. S.; Doody, R.; van Dyck, C. H.; Mulnard, R.; Barakos, J.; Gregg, K. M.; Liu, E.; Lieberburg, I.; Schenk, D.; Black, R.; Grundman, M., A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009, 73 (24), 2061-70.
86. Pfeifer, L. A.; White, L. R.; Ross, G. W.; Petrovitch, H.; Launer, L. J., Cerebral amyloid angiopathy and cognitive function: the HAAS autopsy study. Neurology. 2002, 58 (11), 1629-34.
87. Mangialasche, F.; Solomon, A.; Winblad, B.; Mecocci, P.; Kivipelto, M., Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 2010, 9 (7), 702-16.
88. Morgan, D., Immunotherapy for Alzheimer's disease. J Intern Med. 2011, 269 (1), 54-63.
89. Sperling, R.; Salloway, S.; Brooks, D. J.; Tampieri, D.; Barakos, J.; Fox, N. C.; Raskind, M.; Sabbagh, M.; Honig, L. S.; Porsteinsson, A. P.; Lieberburg, I.; Arrighi, H. M.; Morris, K. A.; Lu, Y.; Liu, E.; Gregg, K. M.; Brashear, H. R.; Kinney, G. G.; Black, R.; Grundman, M., Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 2012, 11 (3), 241-9.
90. Kerchner, G. A.; Boxer, A. L., Bapineuzumab. Expert Opin Biol Ther. 2010, 10 (7), 1121-30.
91. Panza, F.; Frisardi, V.; Imbimbo, B. P.; Seripa, D.; Paris, F.; Santamato, A.; D'Onofrio, G.; Logroscino, G.; Pilotto, A.; Solfrizzi, V., Anti-beta-Amyloid Immunotherapy for Alzheimer's Disease: Focus on Bapineuzumab. Curr Alzheimer Res. 2011.
92. Sperling, R. A randomized, double-blind, placebocontrolled clinical trial of intravenous bapineuzumab in patients with Alzheimer's disease who are apolipoprotein E 4 carriers. http://www2. kenes. com/efns/info/Documents/Sperling_Bapineuzu mab%20IV%20Study%20302_EFNS%20Presentation%20Slides_9-11-2012. pdf (accessed February 13).
93. Salloway, S. A randomized, double-blind, placebocontrolled clinical trial of intravenous bapineuzumab in patients with Alzheimer's disease who are apolipoprotein E 4 non-carriers. http://www2. kenes. com/efns/info/Documents/Salloway_Bapineuzu mab%20IV%20Study%20301_EFNS%20Presentation%20Slides_9-11-2012. pdf (accessed February 13).
94. Keller, D. M. Solanezumab Moderates Cognitive Decline in Alzheimer's. http://www. medscape. com/viewarticle/772476 (accessed February 13).
95. Anderson, P. More Good News for Solanezumab in Alzheimer's. http://www. medscape. com/viewarticle/773824 (accessed February 13).
96. Bohrmann, B.; Baumann, K.; Benz, J.; Gerber, F.; Huber, W.; Knoflach, F.; Messer, J.; Oroszlan, K.; Rauchenberger, R.; Richter, W. F.; Rothe, C.; Urban, M.; Bardroff, M.; Winter, M.; Nordstedt, C.; Loetscher, H., Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J Alzheimers Dis. 2012, 28 (1), 49-69.
97. Ostrowitzki, S.; Deptula, D.; Thurfjell, L.; Barkhof, F.; Bohrmann, B.; Brooks, D. J.; Klunk, W. E.; Ashford, E.; Yoo, K.; Xu, Z. X.; Loetscher, H.; Santarelli, L., Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 2012, 69 (2), 198-207.
98. Fujimoto, Y.; Miyoshi, I.; Ishibashi, T.; Togo, K.; Abe, S.; Kupiec, J. W.; Bednar, M. M., Safety of the anti-amyloid monoclonal antibody ponezumab (PF-04360365) following a single-dose intravenous infusion in Japanese patients with mild-to-moderate Alzheimer's disease: Preliminary results. Alzheimer Dement. 2010, 6 (4 suppl 1), S310.
99. Wood, K. M.; McCush, F.; Conboy, J. J.; Durham, R.; Tate, B.; Bednar, M. N.; Landen, J. W.; Geoghegan, K. F.; K. R., B., IP/MS analysis of human CSF Abeta following a single dose of the Cterminal anti-Abeta antibody ponezumab (PF-04360365) to Alzheimer patients. Alzheimer Dement. 2010, 6 (4 suppl 1), S311.
100. Fagan, T. Pfizer Halts Development of Aβ Antibody. http://www. alzforum. org/new/detail. asp?id=2950 (accessed February 13).
101. Dodel, R.; Neff, F.; Noelker, C.; Pul, R.; Du, Y.; Bacher, M.; Oertel, W., Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence. Drugs. 2010, 70 (5), 513-28.
102. Magga, J.; Puli, L.; Pihlaja, R.; Kanninen, K.; Neulamaa, S.; Malm, T.; Hartig, W.; Grosche, J.; Goldsteins, G.; Tanila, H.; Koistinaho, J.; Koistinaho, M., Human intravenous immunoglobulin provides protection against Abeta toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. J Neuroinflammation. 2010, 7 90.
103. Dodel, R. C.; Du, Y.; Depboylu, C.; Hampel, H.; Frolich, L.; Haag, A.; Hemmeter, U.; Paulsen, S.; Teipel, S. J.; Brettschneider, S.; Spottke, A.; Nolker, C.; Moller, H. J.; Wei, X.; Farlow, M.; Sommer, N.; Oertel, W. H., Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2004, 75 (10), 1472-4.
104. Relkin, N. R.; Szabo, P.; Adamiak, B.; Burgut, T.; Monthe, C.; Lent, R. W.; Younkin, S.; Younkin, L.; Schiff, R.; Weksler, M. E., 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging. 2009, 30 (11), 1728-36.
105. Adekar, S. P.; Klyubin, I.; Macy, S.; Rowan, M. J.; Solomon, A.; Dessain, S. K.; O'Nuallain, B., Inherent anti-amyloidogenic activity of human immunoglobulin gamma heavy chains. J Biol Chem. 2010, 285 (2), 1066-74.
106. Robert, R.; Dolezal, O.; Waddington, L.; Hattarki, M. K.; Cappai, R.; Masters, C. L.; Hudson, P. J.; Wark, K. L., Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers. Protein Eng Des Sel. 2009, 22 (3), 199-208.
107. Giuffrida, M. L.; Caraci, F.; Pignataro, B.; Cataldo, S.; De Bona, P.; Bruno, V.; Molinaro, G.; Pappalardo, G.; Messina, A.; Palmigiano, A.; Garozzo, D.; Nicoletti, F.; Rizzarelli, E.; Copani, A., Beta-amyloid monomers are neuroprotective. J Neurosci. 2009, 29 (34), 10582-7.
108. Lambert, M. P.; Velasco, P. T.; Viola, K. L.; Klein, W. L., Targeting generation of antibodies specific to conformational epitopes of amyloid beta-derived neurotoxins. CNS Neurol Disord Drug Targets. 2009, 8 (1), 65-81.
109. Mangialasche, F.; Solomon, A.; Winblad, B.; Mecocci, P.; Kivipelto, M., Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 2010, 9 (7), 702-16.
110. Salomone, S.; Caraci, F.; Leggio, G. M.; Fedotova, J.; Drago, F., New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br J Clin Pharmacol. 2012, 73 (4), 504-17.
111. Dubois, B.; Feldman, H. H.; Jacova, C.; Cummings, J. L.; Dekosky, S. T.; Barberger-Gateau, P.; Delacourte, A.; Frisoni, G.; Fox, N. C.; Galasko, D.; Gauthier, S.; Hampel, H.; Jicha, G. A.; Meguro, K.; O'Brien, J.; Pasquier, F.; Robert, P.; Rossor, M.; Salloway, S.; Sarazin, M.; de Souza, L. C.; Stern, Y.; Visser, P. J.; Scheltens, P., Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010, 9 (11), 1118-27.
112. A Study of Gantenerumab in Patients With Prodromal Alzheimer's Disease. http://www. clinicaltrials. gov/ct2/results?term=NCT01224106&Sea rch=Search (accessed January 20).
113. Strobel, G.; Zakaib, G. D., Solanezumab Heads for New Phase 3 Trial http://www. alzforum. org/new/detail. asp?id=3345 (accessed February 22).
114. Strobel, G. DIAN Trial Picks Gantenerumab, Solanezumab, Maybe BACE Inhibitor http://www. alzforum. org/new/detail. asp?id=3289 (accessed January 20).
115. Caraci, F.; Leggio, G. M.; Drago, F.; Salomone, S., Epigenetic drugs for alzheimer's disease: Hopes and challenges. Br J Clin Pharmacol. 2013, 75 (4), 1154-5.